R01-CA-36725/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1985	1
1987	1
1988	5
1989	1
1990	3
1991	1
1992	3
1993	3
2024	0

1

Anti-CD3 immunotoxin prevents low-dose STZ/interferon-induced autoimmune diabetes in mouse.

Vallera DA, Carroll SF, Brief S, Blazar BR. Vallera DA, et al. Diabetes. 1992 Apr;41(4):457-64. doi: 10.2337/diab.41.4.457. Diabetes. 1992. PMID: 1376702

2

The effects of aromatic and aliphatic maleimide crosslinkers on anti-CD5 ricin immunotoxins.

Myers DE, Uckun FM, Swaim SE, Vallera DA. Myers DE, et al. J Immunol Methods. 1989 Jul 6;121(1):129-42. doi: 10.1016/0022-1759(89)90428-6. J Immunol Methods. 1989. PMID: 2474026

3

Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.

Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA. Blazar BR, et al. J Immunol. 1993 Jan 1;150(1):265-77. J Immunol. 1993. PMID: 8417127

4

Kupffer cell engraftment across the major histocompatibility barrier in mice: bone marrow origin, class II antigen expression, and antigen-presenting capacity.

Paradis K, Sharp HL, Vallera DA, Blazar BR. Paradis K, et al. J Pediatr Gastroenterol Nutr. 1990 Nov;11(4):525-33. doi: 10.1097/00005176-199011000-00014. J Pediatr Gastroenterol Nutr. 1990. PMID: 2262842

5

Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha.

Blazar BR, Widmer MB, Taylor PA, Vallera DA. Blazar BR, et al. Blood. 1992 Sep 15;80(6):1614-22. Blood. 1992. PMID: 1369829 Free article.

6

In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.

Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA. Blazar BR, et al. J Immunol. 1991 Sep 1;147(5):1492-503. J Immunol. 1991. PMID: 1831826

7

Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administered during the graft-versus-host disease process.

Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Blazar BR, et al. Ann N Y Acad Sci. 1993 Jun 23;685:73-85. doi: 10.1111/j.1749-6632.1993.tb35854.x. Ann N Y Acad Sci. 1993. PMID: 8363278 No abstract available.

8

Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.

Vallera DA, Taylor PA, Aukerman SL, Blazar BR. Vallera DA, et al. Cancer Res. 1993 Sep 15;53(18):4273-80. Cancer Res. 1993. PMID: 8364923

9

Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants.

Blazar BR, Aukerman SL, Vallera DA. Blazar BR, et al. Blood. 1992 Mar 15;79(6):1636-42. Blood. 1992. PMID: 1547353 Free article.

10

Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.

Schmidberger H, King L, Lasky LC, Vallera DA. Schmidberger H, et al. Cancer Res. 1990 Jun 1;50(11):3249-56. Cancer Res. 1990. PMID: 1692258

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year